Rivaroxaban in Orthopedic Surgery — A Change of Paradigm?

Clinical and Applied Thrombosis/Hemostasis

Volumn 15, Issue 6, 2009, Pages 613-620

  Schulman, Sam ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

bleeding; clinical trials; rivaroxaban; venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; MORPHOLINE DERIVATIVE; RIVAROXABAN; THIOPHENE DERIVATIVE;

HUMAN; METHODOLOGY; ORTHOPEDIC SURGERY; PREMEDICATION; REVIEW; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HUMANS; MORPHOLINES; ORTHOPEDIC PROCEDURES; PREMEDICATION; THIOPHENES; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 75549091094     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029609342094     Document Type: Article

References (30)

1. Weitz JI, Hirsh J., Samama MM New antithrombotic drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed.). Chest. 2008; 133(6 suppl): 234S-256S.
2. Geerts WH, Bergqvist D., Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed.). Chest. 2008; 133(6 suppl):381S-453S.
3. Diekema DI, Jones RN Oxazolidinones: a review. Drugs. 2000; 59(1):7-16.
4. Kubitza D., Becka M., Voith B., Zuehlsdorf M., Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005; 78(4):412-421.
5. Weinz C., Buetehorn U., Daehler HP, et al. Pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-in rats and dogs. Xenobiotica. 2005; 35(9):891-910.
6. Blech S., Ebner T., Ludwig-Schwellinger E., Stangier J., Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008; 36(2):386-399.
7. Lang D., Freudenberger C., Weinz C. In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans. Drug Metab Dispos. 2009; 37(5):1046-1055.
8. Gross PL, Weitz JI. New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol. 2008; 28(3):380-386.
9. Eriksson BI, Borris LC, Dahl OE, et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation. 2006; 114(22):2374-2381.
10. Eriksson BI, Borris L., Dahl OE, et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost. 2006; 4(1):121-128.
11. Turpie AG, Fisher WD, Bauer KA, et al. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost. 2005; 3(11): 2479-2486.
12. Eriksson BI, Borris LC, Dahl OE, et al. Dose-escalation study of rivaroxaban (BAY 59-7939)-an oral, direct Factor Xa inhibitor-for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res. 2007; 120(5):685-693.
13. Mueck W., Borris LC, Dahl OE, et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost. 2008; 100(3):453-461.
14. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008; 358(26):2765-2775.
15. Kakkar AK, Brenner B., Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008; 372(9632):31-39.
16. Lassen MR, Ageno W., Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008; 358(26): 2776-2786.
17. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD 4). Lancet. 2009; 373(9676):1673-1680.
18. Quinlan DJ, Eikelboom JW, Dahl OE, Eriksson BI, Sidhu PS, Hirsh J. Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. J Thromb Haemost. 2007; 5(7):1438-1443.
19. Eriksson BI, Dahl OE, Rosencher N., et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007; 5(11):2178-2185.
20. Eriksson BI, Dahl OE, Rosencher N., et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007; 370(9591):949-956.
21. Turpie AG, Bauer KA, Eriksson BI, Lassen MR Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002; 162(16): 1833-1840.
22. Eriksson BI, Wille-Jørgensen P., Kälebo P., et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med. 1997; 337(19):1329-1335.
23. Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis Thromb Haemost. 2009; 101(1):77-85.
24. Agnelli G., Gallus A., Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation. 2007; 116(2):180-187.
25. Buller HR, Lensing AW, Prins MH, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood. 2008; 112(6):2242-2247.
26. Schulman S., Wahlander K., Lundstrom T., Clason SB, Eriksson H. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med. 2003;349(18):1713-1721.
27. Olsson SB Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003; 362(9397):1691-1698.
28. Albers GW, Diener HC, Frison L., et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005; 293: 690-698.
29. Connolly S., Pogue J., Hart R., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006; 367(9526): 1903-1912.
30. The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation; a randomised, open-label, non-inferiority trial. Lancet. 2008; 371(9609):315-321.